: Burning mouth syndrome (BMS) is a condition that remains a diagnostic challenge and is frequently difficult to treat. Rather than being a singular entity, more recent research has suggested that the diagnosis of BMS encompasses a family of syndromes. Of this family, type 3 has been identified as being related to contact dermatitis. Although this subtype has been most commonly associated with dental allergens, several food, cosmetic, and pharmaceutical products have also been identified as allergens related to the onset of BMS. Failure to identify these allergens prevents timely diagnosis and initiation of treatment for patients with BMS related to contact dermatitis. This article identifies the allergens most relevant to this type 3 and describes the commercially available allergy panels needed to ensure that all relevant allergens are included during patch testing. This study also describes approaches to diagnosis of BMS and discusses approaches to treatment based on subtypes of the condition.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/DER.0000000000000565 | DOI Listing |
Contact Dermatitis
January 2025
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Acta Dermatovenerol Croat
November 2024
Prof. Ana Bakija-Konsuo, MD, PhD, Clinic for Dermatovenerology CUTIS, Vukovarska 22, Dubrovnik, Croatia;
We report the case of an 18-month-old boy who developed a phototoxic skin reaction to terbinafine on his scalp, ears, and face in the form of disseminated erythematous plaques, which resembled subacute lupus erythematosus (SCLE) in their clinical presentation. Skin changes appeared a short time after the boy was exposed to sunlight during the period of time when he was treated with oral terbinafine due to Microsporum canis fungal scalp infection. Tinea capitis is a common dermatophyte infection primarily affecting prepubertal children (1).
View Article and Find Full Text PDFBackground Cosmetics have become an integral part of the contemporary lifestyle. Contact dermatitis (CD) is an inflammatory skin disease resulting from exposure to an external chemical present in cosmetics. A patch test is considered the criterion standard method for detecting CD.
View Article and Find Full Text PDFCureus
December 2024
Department of Dermatology and Venereology, Ankara Etlik City Hospital, Ankara, TUR.
Background: Skin problems, typically overlooked in elderly patients hospitalized for systemic diseases, can no longer be ignored.
Objectives: This study aimed to investigate the presence and management of dermatological problems in hospitalized elderly patients.
Materials And Methods: This retrospective study involved dermatology consultations for 712 elderly patients (aged ≥ 65 years) hospitalized between October 2022 and October 2023.
Contact Dermatitis
January 2025
Clinic of Dermatology, University Hospital and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Background: Since its inception in 1980, the MOHL index (% patients who are male, have occupational, hand, or leg dermatitis, respectively) and its later evolutions until the presently used MOAHLFA(P) index (adding % patients with atopic dermatitis, face dermatitis, age 40+ years and positive reaction(s) to ≥ 1 baseline series allergen) have been intended to convey important demographic and clinical information on the patients patch tested in a certain area and time, aiding the interpretation of the observed spectrum of sensitisation.
Objectives: To examine the current usage of the MOAHLFA(P) index and suggest consolidated definitions for its single items.
Methods: A title/abstract search in Medline identified publications mentioning the evolving acronyms.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!